| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Electrocardiography | 189 | 2024 | 961 | 31.730 |
Why?
|
| Myocardial Infarction | 165 | 2023 | 992 | 21.720 |
Why?
|
| ST Elevation Myocardial Infarction | 30 | 2024 | 104 | 12.810 |
Why?
|
| Myocardial Reperfusion Injury | 37 | 2022 | 147 | 10.080 |
Why?
|
| Myocardial Ischemia | 40 | 2022 | 335 | 7.380 |
Why?
|
| Bundle-Branch Block | 18 | 2024 | 35 | 6.390 |
Why?
|
| Acute Coronary Syndrome | 17 | 2024 | 195 | 5.960 |
Why?
|
| Pacemaker, Artificial | 14 | 2024 | 170 | 5.050 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 26 | 2022 | 710 | 5.010 |
Why?
|
| Myocardium | 42 | 2020 | 981 | 4.300 |
Why?
|
| Heptanoic Acids | 17 | 2008 | 77 | 3.970 |
Why?
|
| Cardiac Pacing, Artificial | 13 | 2024 | 111 | 3.910 |
Why?
|
| Pyrroles | 17 | 2008 | 177 | 3.650 |
Why?
|
| Coronary Occlusion | 8 | 2023 | 27 | 3.570 |
Why?
|
| Cardiotonic Agents | 11 | 2024 | 134 | 3.460 |
Why?
|
| Pericarditis | 7 | 2022 | 40 | 3.400 |
Why?
|
| Adenosine | 15 | 2022 | 127 | 3.300 |
Why?
|
| Atrial Fibrillation | 13 | 2024 | 621 | 3.280 |
Why?
|
| Thrombolytic Therapy | 37 | 2020 | 202 | 3.160 |
Why?
|
| Coronary Angiography | 42 | 2024 | 416 | 3.050 |
Why?
|
| Heart Rate | 13 | 2020 | 583 | 2.930 |
Why?
|
| Coronary Artery Disease | 20 | 2024 | 739 | 2.930 |
Why?
|
| Coronary Vessels | 19 | 2023 | 528 | 2.920 |
Why?
|
| Thiazolidinediones | 11 | 2012 | 80 | 2.880 |
Why?
|
| Glucosides | 7 | 2024 | 42 | 2.870 |
Why?
|
| Percutaneous Coronary Intervention | 12 | 2024 | 221 | 2.860 |
Why?
|
| Diabetes Mellitus, Type 2 | 15 | 2024 | 1199 | 2.830 |
Why?
|
| Benzhydryl Compounds | 7 | 2024 | 63 | 2.810 |
Why?
|
| Cardiovascular Agents | 7 | 2023 | 85 | 2.760 |
Why?
|
| Humans | 329 | 2024 | 121045 | 2.720 |
Why?
|
| Cyclooxygenase 2 | 15 | 2016 | 158 | 2.680 |
Why?
|
| Cardiovascular Diseases | 13 | 2023 | 1806 | 2.610 |
Why?
|
| Platelet Aggregation Inhibitors | 13 | 2024 | 254 | 2.600 |
Why?
|
| Diagnosis, Differential | 36 | 2024 | 1870 | 2.560 |
Why?
|
| Ventricular Function, Left | 20 | 2022 | 500 | 2.390 |
Why?
|
| Hypoglycemic Agents | 12 | 2022 | 407 | 2.320 |
Why?
|
| Dipeptidyl-Peptidase IV Inhibitors | 5 | 2019 | 25 | 2.200 |
Why?
|
| Heart Conduction System | 14 | 2023 | 146 | 2.190 |
Why?
|
| Male | 217 | 2024 | 58908 | 2.170 |
Why?
|
| Aspirin | 15 | 2022 | 220 | 2.170 |
Why?
|
| Angioplasty, Balloon, Coronary | 24 | 2016 | 172 | 2.150 |
Why?
|
| Myocardial Reperfusion | 16 | 2011 | 79 | 2.080 |
Why?
|
| Defibrillators, Implantable | 5 | 2019 | 191 | 2.050 |
Why?
|
| Heart Ventricles | 17 | 2021 | 766 | 2.050 |
Why?
|
| Chest Pain | 11 | 2023 | 125 | 2.020 |
Why?
|
| Heart Atria | 8 | 2020 | 308 | 2.000 |
Why?
|
| Ventricular Dysfunction, Left | 13 | 2024 | 365 | 2.000 |
Why?
|
| Purinergic P2Y Receptor Antagonists | 6 | 2022 | 43 | 1.980 |
Why?
|
| Coronary Stenosis | 6 | 2023 | 70 | 1.930 |
Why?
|
| Middle Aged | 140 | 2024 | 25263 | 1.910 |
Why?
|
| Echocardiography | 26 | 2022 | 1065 | 1.890 |
Why?
|
| Aged | 110 | 2024 | 18399 | 1.880 |
Why?
|
| Tetrazoles | 7 | 2021 | 63 | 1.880 |
Why?
|
| Coronary Circulation | 17 | 2019 | 211 | 1.690 |
Why?
|
| Heart | 18 | 2023 | 718 | 1.690 |
Why?
|
| Coronary Disease | 19 | 2007 | 641 | 1.680 |
Why?
|
| Rats, Sprague-Dawley | 25 | 2022 | 1208 | 1.670 |
Why?
|
| Inflammasomes | 7 | 2021 | 149 | 1.640 |
Why?
|
| Animals | 94 | 2022 | 33472 | 1.630 |
Why?
|
| Heart Failure | 16 | 2024 | 2123 | 1.630 |
Why?
|
| Equipment Failure | 7 | 2017 | 121 | 1.560 |
Why?
|
| Tachycardia, Supraventricular | 3 | 2019 | 105 | 1.560 |
Why?
|
| Tachycardia, Ventricular | 10 | 2020 | 196 | 1.550 |
Why?
|
| Dipyridamole | 4 | 2021 | 29 | 1.520 |
Why?
|
| Nitric Oxide Synthase Type III | 12 | 2014 | 221 | 1.510 |
Why?
|
| Rats | 29 | 2022 | 3646 | 1.510 |
Why?
|
| Lipoxins | 8 | 2016 | 12 | 1.450 |
Why?
|
| Anterior Wall Myocardial Infarction | 4 | 2018 | 11 | 1.410 |
Why?
|
| Inferior Wall Myocardial Infarction | 4 | 2020 | 8 | 1.410 |
Why?
|
| Proto-Oncogene Proteins c-akt | 12 | 2021 | 492 | 1.390 |
Why?
|
| Stroke | 7 | 2021 | 945 | 1.390 |
Why?
|
| Anticoagulants | 8 | 2024 | 581 | 1.390 |
Why?
|
| Risk Assessment | 20 | 2023 | 3200 | 1.350 |
Why?
|
| Ventricular Remodeling | 5 | 2020 | 175 | 1.350 |
Why?
|
| Ultrasonic Therapy | 11 | 2007 | 31 | 1.330 |
Why?
|
| Coronary Thrombosis | 8 | 2020 | 33 | 1.330 |
Why?
|
| NLR Family, Pyrin Domain-Containing 3 Protein | 6 | 2021 | 112 | 1.330 |
Why?
|
| Diagnosis, Computer-Assisted | 5 | 2016 | 91 | 1.320 |
Why?
|
| Female | 151 | 2024 | 63993 | 1.310 |
Why?
|
| Arrhythmias, Cardiac | 11 | 2023 | 455 | 1.280 |
Why?
|
| Diabetic Nephropathies | 2 | 2021 | 109 | 1.250 |
Why?
|
| Cardiomyopathy, Hypertrophic | 3 | 2021 | 152 | 1.250 |
Why?
|
| Drug Therapy, Combination | 18 | 2024 | 1139 | 1.240 |
Why?
|
| Nitric Oxide Synthase Type II | 8 | 2010 | 96 | 1.240 |
Why?
|
| Prognosis | 44 | 2022 | 4472 | 1.230 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 3 | 2020 | 207 | 1.200 |
Why?
|
| Myocytes, Cardiac | 13 | 2020 | 617 | 1.180 |
Why?
|
| Predictive Value of Tests | 30 | 2020 | 2055 | 1.180 |
Why?
|
| Atrial Flutter | 2 | 2020 | 31 | 1.170 |
Why?
|
| Ventricular Premature Complexes | 3 | 2017 | 10 | 1.170 |
Why?
|
| Coronary Artery Bypass | 12 | 2019 | 483 | 1.170 |
Why?
|
| Thrombosis | 11 | 2020 | 505 | 1.150 |
Why?
|
| Severity of Illness Index | 17 | 2020 | 2779 | 1.140 |
Why?
|
| Sensitivity and Specificity | 26 | 2019 | 1999 | 1.140 |
Why?
|
| Angiotensin Receptor Antagonists | 2 | 2020 | 119 | 1.140 |
Why?
|
| Ischemic Preconditioning, Myocardial | 4 | 2021 | 10 | 1.130 |
Why?
|
| Heart Diseases | 7 | 2020 | 480 | 1.110 |
Why?
|
| Practice Guidelines as Topic | 5 | 2020 | 1230 | 1.100 |
Why?
|
| Echocardiography, Stress | 3 | 2019 | 16 | 1.100 |
Why?
|
| Wolff-Parkinson-White Syndrome | 4 | 2021 | 73 | 1.090 |
Why?
|
| Ventricular Septum | 2 | 2023 | 16 | 1.070 |
Why?
|
| Randomized Controlled Trials as Topic | 13 | 2022 | 1023 | 1.050 |
Why?
|
| Apoptosis | 11 | 2020 | 1788 | 1.030 |
Why?
|
| Cardiomyopathies | 3 | 2022 | 476 | 1.020 |
Why?
|
| Fibrinolytic Agents | 17 | 2022 | 201 | 1.010 |
Why?
|
| Algorithms | 11 | 2021 | 1568 | 1.000 |
Why?
|
| Cyclic AMP-Dependent Protein Kinases | 6 | 2012 | 160 | 0.990 |
Why?
|
| Diagnostic Errors | 6 | 2014 | 313 | 0.990 |
Why?
|
| Adrenergic beta-Antagonists | 8 | 2022 | 234 | 0.990 |
Why?
|
| Risk Factors | 41 | 2022 | 9603 | 0.980 |
Why?
|
| AMP-Activated Protein Kinases | 5 | 2021 | 166 | 0.980 |
Why?
|
| Phosphodiesterase 3 Inhibitors | 3 | 2014 | 7 | 0.970 |
Why?
|
| Hypertrophy, Left Ventricular | 7 | 2020 | 106 | 0.970 |
Why?
|
| Disease Models, Animal | 30 | 2020 | 4255 | 0.970 |
Why?
|
| Aortic Valve Stenosis | 4 | 2023 | 319 | 0.960 |
Why?
|
| Phosphorylation | 16 | 2020 | 1613 | 0.950 |
Why?
|
| Treatment Outcome | 42 | 2023 | 11680 | 0.950 |
Why?
|
| Peptides | 8 | 2016 | 798 | 0.940 |
Why?
|
| Diabetes Mellitus, Experimental | 7 | 2019 | 139 | 0.940 |
Why?
|
| Hydrazones | 1 | 2024 | 19 | 0.940 |
Why?
|
| MicroRNAs | 6 | 2019 | 835 | 0.930 |
Why?
|
| Dipeptidyl Peptidase 4 | 3 | 2019 | 21 | 0.920 |
Why?
|
| Hypertension, Pulmonary | 2 | 2020 | 422 | 0.920 |
Why?
|
| Pyridazines | 1 | 2024 | 49 | 0.910 |
Why?
|
| Anticholesteremic Agents | 5 | 2019 | 230 | 0.910 |
Why?
|
| Myocardial Revascularization | 6 | 2019 | 96 | 0.900 |
Why?
|
| Hemodynamics | 8 | 2024 | 833 | 0.900 |
Why?
|
| Up-Regulation | 10 | 2018 | 871 | 0.890 |
Why?
|
| Streptokinase | 14 | 2004 | 20 | 0.880 |
Why?
|
| Eicosanoids | 3 | 2012 | 13 | 0.850 |
Why?
|
| Venoms | 2 | 2013 | 20 | 0.850 |
Why?
|
| No-Reflow Phenomenon | 2 | 2019 | 9 | 0.850 |
Why?
|
| PTEN Phosphohydrolase | 6 | 2014 | 262 | 0.840 |
Why?
|
| Pericarditis, Constrictive | 1 | 2022 | 5 | 0.840 |
Why?
|
| Syncope | 4 | 2016 | 52 | 0.830 |
Why?
|
| Rosuvastatin Calcium | 3 | 2017 | 41 | 0.830 |
Why?
|
| Triazoles | 3 | 2014 | 138 | 0.830 |
Why?
|
| Action Potentials | 4 | 2020 | 499 | 0.830 |
Why?
|
| Atrioventricular Block | 2 | 2020 | 39 | 0.820 |
Why?
|
| Glucagon-Like Peptide-1 Receptor | 4 | 2022 | 69 | 0.820 |
Why?
|
| Reproducibility of Results | 17 | 2019 | 2787 | 0.820 |
Why?
|
| Dose-Response Relationship, Drug | 14 | 2021 | 1672 | 0.810 |
Why?
|
| Aged, 80 and over | 24 | 2024 | 6091 | 0.810 |
Why?
|
| Digitalis | 1 | 2021 | 3 | 0.800 |
Why?
|
| Time Factors | 32 | 2023 | 5975 | 0.790 |
Why?
|
| Ischemic Postconditioning | 1 | 2021 | 4 | 0.780 |
Why?
|
| Vitamin K | 2 | 2024 | 35 | 0.780 |
Why?
|
| Adamantane | 2 | 2018 | 7 | 0.760 |
Why?
|
| Acute Disease | 11 | 2020 | 1086 | 0.760 |
Why?
|
| Ischemia | 5 | 2022 | 307 | 0.760 |
Why?
|
| Insulins | 1 | 2021 | 17 | 0.760 |
Why?
|
| Simvastatin | 4 | 2010 | 75 | 0.740 |
Why?
|
| Dipeptides | 2 | 2018 | 59 | 0.740 |
Why?
|
| Intermittent Claudication | 1 | 2021 | 48 | 0.730 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 2 | 2011 | 51 | 0.730 |
Why?
|
| Antifibrinolytic Agents | 1 | 2020 | 33 | 0.720 |
Why?
|
| Retrospective Studies | 42 | 2023 | 15563 | 0.700 |
Why?
|
| Administration, Oral | 9 | 2021 | 651 | 0.700 |
Why?
|
| Tachycardia, Atrioventricular Nodal Reentry | 1 | 2020 | 22 | 0.700 |
Why?
|
| Foreign-Body Migration | 2 | 2018 | 72 | 0.700 |
Why?
|
| Sodium-Glucose Transporter 2 | 3 | 2021 | 14 | 0.700 |
Why?
|
| Patient Admission | 8 | 2007 | 184 | 0.680 |
Why?
|
| Linagliptin | 1 | 2019 | 4 | 0.680 |
Why?
|
| Diabetic Cardiomyopathies | 4 | 2020 | 15 | 0.680 |
Why?
|
| Editorial Policies | 1 | 2020 | 49 | 0.670 |
Why?
|
| Renin-Angiotensin System | 1 | 2020 | 93 | 0.670 |
Why?
|
| Blood Coagulation | 6 | 2002 | 118 | 0.670 |
Why?
|
| Ultrasonography, Interventional | 8 | 2002 | 194 | 0.660 |
Why?
|
| Microcirculation | 1 | 2019 | 94 | 0.660 |
Why?
|
| Data Display | 1 | 2019 | 11 | 0.650 |
Why?
|
| Guidelines as Topic | 1 | 2020 | 189 | 0.650 |
Why?
|
| Sodium-Hydrogen Exchanger 1 | 1 | 2018 | 3 | 0.650 |
Why?
|
| Gastrointestinal Hemorrhage | 4 | 2024 | 220 | 0.650 |
Why?
|
| Outpatients | 1 | 2021 | 253 | 0.640 |
Why?
|
| Time-to-Treatment | 1 | 2020 | 182 | 0.630 |
Why?
|
| PPAR gamma | 4 | 2017 | 92 | 0.630 |
Why?
|
| Heart Neoplasms | 2 | 2019 | 102 | 0.630 |
Why?
|
| Signal Processing, Computer-Assisted | 6 | 2019 | 117 | 0.630 |
Why?
|
| Sulfonamides | 4 | 2014 | 257 | 0.630 |
Why?
|
| Electric Countershock | 2 | 2017 | 67 | 0.620 |
Why?
|
| Magnetic Resonance Imaging | 9 | 2022 | 3403 | 0.620 |
Why?
|
| Stroke Volume | 11 | 2022 | 446 | 0.600 |
Why?
|
| Incretins | 1 | 2018 | 25 | 0.590 |
Why?
|
| Glucagon-Like Peptide 1 | 3 | 2012 | 67 | 0.590 |
Why?
|
| Signal Transduction | 19 | 2020 | 4498 | 0.590 |
Why?
|
| Kidney | 4 | 2021 | 1329 | 0.590 |
Why?
|
| Guideline Adherence | 1 | 2020 | 371 | 0.580 |
Why?
|
| Tachycardia | 1 | 2017 | 67 | 0.580 |
Why?
|
| Cyclic AMP | 3 | 2012 | 249 | 0.580 |
Why?
|
| Pulmonary Heart Disease | 1 | 2017 | 4 | 0.580 |
Why?
|
| Ischemic Preconditioning | 3 | 2019 | 17 | 0.580 |
Why?
|
| Cardiac Resynchronization Therapy Devices | 1 | 2017 | 13 | 0.570 |
Why?
|
| Artifacts | 3 | 2007 | 99 | 0.570 |
Why?
|
| Periodicals as Topic | 1 | 2020 | 184 | 0.570 |
Why?
|
| Triage | 3 | 2014 | 139 | 0.570 |
Why?
|
| Cardiac Resynchronization Therapy | 1 | 2017 | 28 | 0.560 |
Why?
|
| Tissue Plasminogen Activator | 11 | 2004 | 112 | 0.550 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 4 | 2010 | 94 | 0.550 |
Why?
|
| Cardiomegaly | 1 | 2017 | 137 | 0.540 |
Why?
|
| Cyclooxygenase Inhibitors | 5 | 2007 | 64 | 0.540 |
Why?
|
| Adult | 48 | 2022 | 28363 | 0.540 |
Why?
|
| Receptors, Glucagon | 2 | 2013 | 29 | 0.530 |
Why?
|
| Diabetic Angiopathies | 1 | 2016 | 59 | 0.530 |
Why?
|
| Aneurysm, False | 3 | 2006 | 97 | 0.520 |
Why?
|
| Anti-Inflammatory Agents | 3 | 2021 | 278 | 0.520 |
Why?
|
| Angina, Unstable | 4 | 2006 | 51 | 0.520 |
Why?
|
| Cardiac Catheterization | 6 | 2018 | 630 | 0.510 |
Why?
|
| Immunoblotting | 6 | 2012 | 312 | 0.510 |
Why?
|
| Sick Sinus Syndrome | 2 | 2014 | 12 | 0.510 |
Why?
|
| Clinical Trials as Topic | 4 | 2018 | 1075 | 0.510 |
Why?
|
| Coronary Vasospasm | 2 | 2014 | 10 | 0.510 |
Why?
|
| Dyspnea | 3 | 2013 | 148 | 0.500 |
Why?
|
| Heart Aneurysm | 3 | 2011 | 38 | 0.490 |
Why?
|
| Fibroblasts | 2 | 2018 | 877 | 0.490 |
Why?
|
| Drug Interactions | 7 | 2024 | 252 | 0.490 |
Why?
|
| Atrial Premature Complexes | 1 | 2014 | 1 | 0.490 |
Why?
|
| Fluorobenzenes | 1 | 2014 | 38 | 0.470 |
Why?
|
| Postoperative Complications | 7 | 2019 | 2869 | 0.470 |
Why?
|
| Stents | 7 | 2018 | 684 | 0.470 |
Why?
|
| Mice | 17 | 2021 | 17432 | 0.470 |
Why?
|
| Biomedical Research | 1 | 2020 | 503 | 0.460 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 3 | 2014 | 60 | 0.460 |
Why?
|
| Phospholipases A2, Cytosolic | 2 | 2011 | 2 | 0.460 |
Why?
|
| Diabetes Complications | 3 | 2014 | 195 | 0.460 |
Why?
|
| Sinoatrial Block | 1 | 2013 | 1 | 0.460 |
Why?
|
| Hydroxyethyl Starch Derivatives | 3 | 2003 | 8 | 0.450 |
Why?
|
| Equipment Failure Analysis | 1 | 2013 | 88 | 0.440 |
Why?
|
| Hospital Mortality | 11 | 2022 | 976 | 0.440 |
Why?
|
| Drug Discovery | 1 | 2015 | 174 | 0.440 |
Why?
|
| Technetium Tc 99m Sestamibi | 7 | 2005 | 25 | 0.440 |
Why?
|
| Enzyme Activation | 5 | 2020 | 620 | 0.430 |
Why?
|
| Heart Block | 3 | 2016 | 41 | 0.430 |
Why?
|
| 6-Ketoprostaglandin F1 alpha | 5 | 2014 | 10 | 0.430 |
Why?
|
| Arachidonate 5-Lipoxygenase | 2 | 2012 | 3 | 0.420 |
Why?
|
| Diastole | 3 | 2024 | 170 | 0.420 |
Why?
|
| Blood Glucose | 8 | 2021 | 1100 | 0.410 |
Why?
|
| Mice, Inbred C57BL | 11 | 2021 | 4340 | 0.410 |
Why?
|
| Nitric Oxide Synthase | 3 | 2008 | 187 | 0.410 |
Why?
|
| Endoplasmic Reticulum Stress | 1 | 2013 | 122 | 0.400 |
Why?
|
| Accidental Falls | 1 | 2013 | 106 | 0.400 |
Why?
|
| NF-kappa B | 2 | 2020 | 461 | 0.400 |
Why?
|
| Decision Making, Computer-Assisted | 2 | 2011 | 19 | 0.400 |
Why?
|
| Fumarates | 1 | 2011 | 15 | 0.400 |
Why?
|
| Ventricular Septal Rupture | 2 | 2002 | 3 | 0.400 |
Why?
|
| Bradycardia | 3 | 2016 | 62 | 0.390 |
Why?
|
| Death, Sudden, Cardiac | 3 | 2007 | 245 | 0.390 |
Why?
|
| Coronary Vessel Anomalies | 2 | 2006 | 264 | 0.390 |
Why?
|
| Recovery of Function | 2 | 2013 | 429 | 0.390 |
Why?
|
| Lipopolysaccharides | 2 | 2018 | 289 | 0.390 |
Why?
|
| Receptor, Angiotensin, Type 1 | 1 | 2011 | 60 | 0.390 |
Why?
|
| Pyrimidines | 1 | 2014 | 371 | 0.380 |
Why?
|
| Amides | 1 | 2011 | 82 | 0.380 |
Why?
|
| Valine | 1 | 2011 | 106 | 0.380 |
Why?
|
| Phosphodiesterase Inhibitors | 4 | 2007 | 53 | 0.380 |
Why?
|
| Fibrosis | 6 | 2020 | 422 | 0.380 |
Why?
|
| Diabetes Mellitus | 4 | 2014 | 837 | 0.380 |
Why?
|
| Glyburide | 2 | 2008 | 22 | 0.380 |
Why?
|
| Hyperlipidemias | 2 | 2012 | 172 | 0.370 |
Why?
|
| Proton Pump Inhibitors | 2 | 2024 | 252 | 0.360 |
Why?
|
| Heparin | 6 | 2003 | 231 | 0.360 |
Why?
|
| Ventricular Dysfunction, Right | 1 | 2011 | 78 | 0.360 |
Why?
|
| Platelet Glycoprotein GPIIb-IIIa Complex | 3 | 2008 | 61 | 0.350 |
Why?
|
| Torsades de Pointes | 1 | 2010 | 6 | 0.350 |
Why?
|
| Atherosclerosis | 4 | 2022 | 813 | 0.350 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2019 | 948 | 0.350 |
Why?
|
| Rabbits | 11 | 2007 | 719 | 0.350 |
Why?
|
| Ofloxacin | 1 | 2010 | 32 | 0.350 |
Why?
|
| Drug Synergism | 5 | 2016 | 234 | 0.340 |
Why?
|
| Levofloxacin | 1 | 2010 | 46 | 0.340 |
Why?
|
| Reperfusion Injury | 2 | 2007 | 103 | 0.340 |
Why?
|
| Pyrazines | 1 | 2010 | 75 | 0.340 |
Why?
|
| Arteriosclerosis | 3 | 2004 | 139 | 0.340 |
Why?
|
| Insulin Resistance | 1 | 2014 | 634 | 0.330 |
Why?
|
| Eicosapentaenoic Acid | 1 | 2010 | 78 | 0.330 |
Why?
|
| Incidence | 10 | 2013 | 2965 | 0.320 |
Why?
|
| Aortic Valve | 5 | 2023 | 425 | 0.320 |
Why?
|
| Leukotriene B4 | 1 | 2008 | 7 | 0.320 |
Why?
|
| Sulfonylurea Compounds | 1 | 2008 | 15 | 0.320 |
Why?
|
| Liver Neoplasms | 1 | 2019 | 1373 | 0.310 |
Why?
|
| Recurrence | 10 | 2013 | 1381 | 0.310 |
Why?
|
| Endothelium, Vascular | 3 | 2007 | 522 | 0.310 |
Why?
|
| Food-Drug Interactions | 1 | 2008 | 10 | 0.310 |
Why?
|
| Transcatheter Aortic Valve Replacement | 2 | 2021 | 186 | 0.300 |
Why?
|
| Coffee | 1 | 2008 | 23 | 0.300 |
Why?
|
| Prasugrel Hydrochloride | 2 | 2019 | 21 | 0.300 |
Why?
|
| Azetidines | 1 | 2008 | 55 | 0.300 |
Why?
|
| Logistic Models | 14 | 2020 | 1741 | 0.300 |
Why?
|
| Collateral Circulation | 4 | 2005 | 42 | 0.290 |
Why?
|
| Caffeine | 1 | 2008 | 69 | 0.290 |
Why?
|
| Myocardial Stunning | 3 | 1996 | 21 | 0.290 |
Why?
|
| Prostaglandin D2 | 1 | 2007 | 7 | 0.290 |
Why?
|
| Clinical Competence | 1 | 2014 | 966 | 0.290 |
Why?
|
| Pericardial Effusion | 3 | 2005 | 64 | 0.290 |
Why?
|
| Prospective Studies | 17 | 2022 | 5854 | 0.290 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2019 | 1977 | 0.290 |
Why?
|
| Dyslipidemias | 1 | 2010 | 227 | 0.280 |
Why?
|
| Gene Expression Regulation | 6 | 2019 | 2539 | 0.280 |
Why?
|
| CARD Signaling Adaptor Proteins | 2 | 2017 | 44 | 0.280 |
Why?
|
| Oxazoles | 2 | 2017 | 27 | 0.280 |
Why?
|
| Clinical Decision-Making | 2 | 2019 | 262 | 0.270 |
Why?
|
| Piperazines | 2 | 2006 | 227 | 0.270 |
Why?
|
| PPAR alpha | 2 | 2017 | 54 | 0.270 |
Why?
|
| Pyrrolidines | 1 | 2006 | 36 | 0.270 |
Why?
|
| Thiophenes | 2 | 2017 | 60 | 0.270 |
Why?
|
| Heart Transplantation | 1 | 2013 | 856 | 0.270 |
Why?
|
| Societies, Medical | 3 | 2020 | 662 | 0.260 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 3 | 2010 | 111 | 0.260 |
Why?
|
| Pericardium | 2 | 2022 | 82 | 0.260 |
Why?
|
| Waiting Lists | 1 | 2007 | 218 | 0.250 |
Why?
|
| Surgical Procedures, Operative | 1 | 2007 | 181 | 0.250 |
Why?
|
| Femoral Artery | 4 | 2007 | 168 | 0.250 |
Why?
|
| Accidents, Traffic | 1 | 2006 | 98 | 0.250 |
Why?
|
| Hospitalization | 7 | 2022 | 1717 | 0.250 |
Why?
|
| Prostaglandins | 1 | 2005 | 48 | 0.250 |
Why?
|
| Cells, Cultured | 9 | 2018 | 3068 | 0.250 |
Why?
|
| Munchausen Syndrome | 1 | 2004 | 4 | 0.250 |
Why?
|
| Glucose | 2 | 2021 | 880 | 0.250 |
Why?
|
| Pericardiocentesis | 2 | 2005 | 16 | 0.240 |
Why?
|
| Ticlopidine | 2 | 2015 | 29 | 0.240 |
Why?
|
| Tyrosine | 3 | 2011 | 167 | 0.240 |
Why?
|
| Hypotension, Orthostatic | 1 | 2004 | 16 | 0.240 |
Why?
|
| Electric Stimulation Therapy | 1 | 2005 | 98 | 0.240 |
Why?
|
| Aortic Rupture | 1 | 2006 | 103 | 0.240 |
Why?
|
| Heart Failure, Diastolic | 1 | 2024 | 10 | 0.240 |
Why?
|
| Gastroparesis | 1 | 2005 | 66 | 0.240 |
Why?
|
| Aortic Coarctation | 1 | 2006 | 102 | 0.240 |
Why?
|
| Cause of Death | 3 | 2018 | 442 | 0.240 |
Why?
|
| Body Weight | 6 | 2012 | 963 | 0.240 |
Why?
|
| Intraoperative Complications | 1 | 2006 | 169 | 0.240 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 6 | 2005 | 103 | 0.230 |
Why?
|
| Creatinine | 3 | 2021 | 377 | 0.230 |
Why?
|
| Heart Valve Prosthesis | 4 | 2004 | 293 | 0.230 |
Why?
|
| Patient Discharge | 3 | 2006 | 485 | 0.230 |
Why?
|
| Tetralogy of Fallot | 1 | 2006 | 160 | 0.230 |
Why?
|
| Albumins | 2 | 2021 | 91 | 0.230 |
Why?
|
| Vasodilator Agents | 2 | 2021 | 202 | 0.230 |
Why?
|
| Analysis of Variance | 7 | 2007 | 995 | 0.230 |
Why?
|
| Takotsubo Cardiomyopathy | 2 | 2015 | 18 | 0.230 |
Why?
|
| Heart Rupture, Post-Infarction | 1 | 2003 | 6 | 0.230 |
Why?
|
| Consensus | 4 | 2014 | 601 | 0.220 |
Why?
|
| Emergency Service, Hospital | 2 | 2023 | 1049 | 0.220 |
Why?
|
| Bundle of His | 2 | 2022 | 8 | 0.220 |
Why?
|
| Necrosis | 5 | 2006 | 209 | 0.220 |
Why?
|
| Blood | 2 | 2001 | 99 | 0.220 |
Why?
|
| Phospholipases A2 | 3 | 2010 | 35 | 0.220 |
Why?
|
| Protective Agents | 2 | 2016 | 30 | 0.220 |
Why?
|
| Hindlimb | 2 | 2007 | 76 | 0.220 |
Why?
|
| Radiopharmaceuticals | 5 | 2005 | 158 | 0.220 |
Why?
|
| Hernia, Hiatal | 1 | 2003 | 53 | 0.210 |
Why?
|
| Mice, Knockout | 7 | 2017 | 3767 | 0.210 |
Why?
|
| Potassium Channels | 1 | 2004 | 156 | 0.210 |
Why?
|
| Echocardiography, Doppler, Color | 3 | 2004 | 113 | 0.210 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2004 | 190 | 0.210 |
Why?
|
| Inflammation Mediators | 3 | 2020 | 234 | 0.210 |
Why?
|
| Follow-Up Studies | 10 | 2013 | 4957 | 0.210 |
Why?
|
| In Vitro Techniques | 7 | 2013 | 968 | 0.210 |
Why?
|
| Drug Administration Schedule | 5 | 2021 | 731 | 0.210 |
Why?
|
| Pulmonary Artery | 2 | 1999 | 437 | 0.210 |
Why?
|
| Patients | 1 | 2023 | 120 | 0.200 |
Why?
|
| Cholesterol, LDL | 2 | 2019 | 554 | 0.200 |
Why?
|
| Antacids | 1 | 2022 | 26 | 0.200 |
Why?
|
| Aorta | 1 | 2006 | 518 | 0.200 |
Why?
|
| Morphine Derivatives | 1 | 2022 | 6 | 0.200 |
Why?
|
| Circulating MicroRNA | 2 | 2019 | 8 | 0.200 |
Why?
|
| Pyrazoles | 3 | 2024 | 295 | 0.200 |
Why?
|
| Apyrase | 1 | 2022 | 18 | 0.200 |
Why?
|
| Histamine H2 Antagonists | 1 | 2022 | 49 | 0.200 |
Why?
|
| Hematoxylin | 1 | 2021 | 7 | 0.190 |
Why?
|
| Ketosis | 1 | 2021 | 15 | 0.190 |
Why?
|
| Eosine Yellowish-(YS) | 1 | 2021 | 8 | 0.190 |
Why?
|
| Periodic Acid | 1 | 2021 | 7 | 0.190 |
Why?
|
| Ultrasonics | 1 | 2001 | 36 | 0.190 |
Why?
|
| Digoxin | 1 | 2021 | 43 | 0.190 |
Why?
|
| Fibrinolysis | 1 | 2001 | 37 | 0.190 |
Why?
|
| Electrodes, Implanted | 1 | 2002 | 151 | 0.190 |
Why?
|
| Heart Rupture | 1 | 2001 | 3 | 0.190 |
Why?
|
| Terminology as Topic | 2 | 2017 | 220 | 0.190 |
Why?
|
| Disease Progression | 6 | 2020 | 1968 | 0.190 |
Why?
|
| Hypertension | 5 | 2018 | 1263 | 0.190 |
Why?
|
| Enzyme Induction | 2 | 2014 | 105 | 0.190 |
Why?
|
| Cystatin C | 1 | 2021 | 48 | 0.190 |
Why?
|
| Aortic Aneurysm | 1 | 2003 | 186 | 0.190 |
Why?
|
| Pulmonary Embolism | 1 | 2003 | 171 | 0.190 |
Why?
|
| Isoquinolines | 2 | 2012 | 39 | 0.180 |
Why?
|
| Gadolinium | 2 | 2018 | 102 | 0.180 |
Why?
|
| Pulmonary Wedge Pressure | 1 | 2020 | 50 | 0.180 |
Why?
|
| Mitral Valve Insufficiency | 1 | 2002 | 155 | 0.180 |
Why?
|
| Electroacupuncture | 1 | 2020 | 8 | 0.180 |
Why?
|
| Syndrome | 4 | 2007 | 1116 | 0.180 |
Why?
|
| Muscle, Skeletal | 3 | 2014 | 925 | 0.180 |
Why?
|
| Fatty Acids, Omega-3 | 1 | 2021 | 69 | 0.180 |
Why?
|
| Therapeutic Equivalency | 1 | 2020 | 13 | 0.180 |
Why?
|
| Survival Rate | 7 | 2018 | 1973 | 0.180 |
Why?
|
| Inflammation | 3 | 2022 | 1396 | 0.180 |
Why?
|
| Odds Ratio | 7 | 2020 | 1215 | 0.180 |
Why?
|
| bcl-2-Associated X Protein | 2 | 2010 | 71 | 0.170 |
Why?
|
| Sonication | 1 | 1999 | 8 | 0.170 |
Why?
|
| Dobutamine | 2 | 2019 | 56 | 0.170 |
Why?
|
| Cohort Studies | 6 | 2018 | 4577 | 0.170 |
Why?
|
| Journal Impact Factor | 1 | 2020 | 22 | 0.170 |
Why?
|
| Apoptosis Regulatory Proteins | 2 | 2020 | 150 | 0.170 |
Why?
|
| Secondary Prevention | 3 | 2019 | 209 | 0.170 |
Why?
|
| Diabetes Mellitus, Type 1 | 2 | 2021 | 777 | 0.170 |
Why?
|
| Atrial Natriuretic Factor | 2 | 2019 | 52 | 0.170 |
Why?
|
| Abnormalities, Multiple | 1 | 2006 | 974 | 0.170 |
Why?
|
| Fibrin | 1 | 1999 | 64 | 0.170 |
Why?
|
| Diabetic Ketoacidosis | 1 | 2021 | 153 | 0.170 |
Why?
|
| Down-Regulation | 2 | 2018 | 700 | 0.170 |
Why?
|
| Arterio-Arterial Fistula | 1 | 1999 | 8 | 0.170 |
Why?
|
| Anti-Arrhythmia Agents | 2 | 2015 | 218 | 0.160 |
Why?
|
| Swine | 3 | 2018 | 1161 | 0.160 |
Why?
|
| Artificial Intelligence | 1 | 2022 | 226 | 0.160 |
Why?
|
| Smoking | 3 | 2007 | 1021 | 0.160 |
Why?
|
| Injections, Intravenous | 2 | 2010 | 255 | 0.160 |
Why?
|
| Endoglin | 1 | 2019 | 21 | 0.160 |
Why?
|
| Shock, Cardiogenic | 4 | 2020 | 188 | 0.160 |
Why?
|
| Angina Pectoris | 3 | 1996 | 57 | 0.160 |
Why?
|
| Blood Pressure | 5 | 2013 | 1310 | 0.160 |
Why?
|
| Aorta, Thoracic | 1 | 2003 | 489 | 0.160 |
Why?
|
| Blotting, Western | 2 | 2012 | 1100 | 0.160 |
Why?
|
| Nitric Oxide Synthase Type I | 2 | 2010 | 29 | 0.160 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2019 | 53 | 0.160 |
Why?
|
| Asymptomatic Diseases | 1 | 2019 | 71 | 0.160 |
Why?
|
| Extracellular Vesicles | 1 | 2019 | 44 | 0.160 |
Why?
|
| Multimorbidity | 1 | 2018 | 18 | 0.160 |
Why?
|
| Hemorrhage | 1 | 2022 | 459 | 0.160 |
Why?
|
| HSP70 Heat-Shock Proteins | 1 | 2018 | 67 | 0.160 |
Why?
|
| Cyclooxygenase 1 | 2 | 2010 | 40 | 0.160 |
Why?
|
| Cardiomyopathy, Alcoholic | 1 | 2018 | 4 | 0.160 |
Why?
|
| Statistics as Topic | 3 | 2004 | 237 | 0.160 |
Why?
|
| Receptors, Opioid, delta | 2 | 2009 | 12 | 0.160 |
Why?
|
| Protein Kinase Inhibitors | 3 | 2013 | 513 | 0.160 |
Why?
|
| Erythrocytes | 1 | 2019 | 207 | 0.160 |
Why?
|
| Radiographic Image Enhancement | 1 | 2018 | 40 | 0.160 |
Why?
|
| RNA, Messenger | 3 | 2016 | 2826 | 0.150 |
Why?
|
| Echocardiography, Transesophageal | 4 | 2006 | 241 | 0.150 |
Why?
|
| Administration, Intravenous | 1 | 2018 | 142 | 0.150 |
Why?
|
| Dexmedetomidine | 1 | 2018 | 44 | 0.150 |
Why?
|
| Anti-Bacterial Agents | 1 | 2010 | 2370 | 0.150 |
Why?
|
| Membrane Proteins | 3 | 2012 | 1524 | 0.150 |
Why?
|
| Receptors, Purinergic P1 | 2 | 2008 | 10 | 0.150 |
Why?
|
| Models, Cardiovascular | 3 | 2010 | 168 | 0.150 |
Why?
|
| Troponin | 1 | 2018 | 70 | 0.150 |
Why?
|
| Receptors, Adrenergic, beta-2 | 2 | 2009 | 86 | 0.150 |
Why?
|
| Coronary Artery Bypass, Off-Pump | 1 | 2017 | 24 | 0.150 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2020 | 429 | 0.150 |
Why?
|
| Iliac Artery | 1 | 1998 | 76 | 0.150 |
Why?
|
| Serum Albumin | 1 | 1998 | 114 | 0.150 |
Why?
|
| Combined Modality Therapy | 7 | 2003 | 1240 | 0.150 |
Why?
|
| Clinical Trials, Phase II as Topic | 3 | 2018 | 71 | 0.150 |
Why?
|
| L-Selectin | 1 | 1997 | 22 | 0.150 |
Why?
|
| E-Selectin | 1 | 1997 | 42 | 0.150 |
Why?
|
| Radiography, Thoracic | 1 | 2018 | 151 | 0.150 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 2 | 2010 | 88 | 0.150 |
Why?
|
| Riots | 1 | 1997 | 2 | 0.150 |
Why?
|
| Magnetic Resonance Imaging, Cine | 1 | 2018 | 146 | 0.150 |
Why?
|
| Hypnotics and Sedatives | 1 | 2018 | 135 | 0.140 |
Why?
|
| Arabs | 1 | 1997 | 28 | 0.140 |
Why?
|
| Infarction | 1 | 1997 | 21 | 0.140 |
Why?
|
| P-Selectin | 1 | 1997 | 77 | 0.140 |
Why?
|
| Cardiovascular System | 1 | 2018 | 99 | 0.140 |
Why?
|
| Oligosaccharides | 1 | 1997 | 72 | 0.140 |
Why?
|
| Radiography | 5 | 2006 | 798 | 0.140 |
Why?
|
| Pattern Recognition, Automated | 2 | 2013 | 45 | 0.140 |
Why?
|
| Rats, Zucker | 1 | 2016 | 41 | 0.140 |
Why?
|
| Gangliosides | 1 | 1997 | 64 | 0.140 |
Why?
|
| Ubiquinone | 1 | 1996 | 24 | 0.140 |
Why?
|
| Comorbidity | 2 | 2018 | 1472 | 0.140 |
Why?
|
| Liraglutide | 1 | 2016 | 13 | 0.140 |
Why?
|
| Israel | 4 | 2002 | 43 | 0.140 |
Why?
|
| Equipment Design | 1 | 2019 | 586 | 0.140 |
Why?
|
| Intramolecular Oxidoreductases | 2 | 2008 | 56 | 0.140 |
Why?
|
| Acute Kidney Injury | 2 | 1994 | 590 | 0.140 |
Why?
|
| Blood Platelets | 1 | 2019 | 320 | 0.140 |
Why?
|
| Arteries | 1 | 1997 | 211 | 0.140 |
Why?
|
| Violence | 1 | 1997 | 111 | 0.140 |
Why?
|
| Neoplasm Metastasis | 1 | 2019 | 650 | 0.130 |
Why?
|
| Kidney Tubules, Proximal | 1 | 2017 | 110 | 0.130 |
Why?
|
| Evidence-Based Medicine | 1 | 2020 | 590 | 0.130 |
Why?
|
| Staining and Labeling | 1 | 1997 | 187 | 0.130 |
Why?
|
| United States | 7 | 2022 | 10332 | 0.130 |
Why?
|
| Interleukin-1beta | 1 | 2016 | 159 | 0.130 |
Why?
|
| Observer Variation | 3 | 2014 | 297 | 0.130 |
Why?
|
| Cell Survival | 3 | 2017 | 818 | 0.130 |
Why?
|
| Nicotinic Agonists | 1 | 1996 | 44 | 0.130 |
Why?
|
| Cytochrome P-450 Enzyme System | 2 | 2008 | 135 | 0.130 |
Why?
|
| Coitus | 1 | 2015 | 20 | 0.130 |
Why?
|
| Pleasure | 1 | 2015 | 12 | 0.130 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2008 | 792 | 0.130 |
Why?
|
| Rest | 1 | 2015 | 58 | 0.130 |
Why?
|
| Phospholipases A | 2 | 2006 | 39 | 0.130 |
Why?
|
| Injections, Intraperitoneal | 1 | 2015 | 74 | 0.130 |
Why?
|
| Texas | 4 | 2013 | 3508 | 0.130 |
Why?
|
| RNA Interference | 2 | 2017 | 495 | 0.130 |
Why?
|
| Chi-Square Distribution | 5 | 2011 | 568 | 0.130 |
Why?
|
| Parkinson Disease | 1 | 2002 | 658 | 0.120 |
Why?
|
| Contrast Media | 4 | 2017 | 452 | 0.120 |
Why?
|
| Risk | 1 | 2017 | 737 | 0.120 |
Why?
|
| Creatine Kinase, MB Form | 2 | 2012 | 18 | 0.120 |
Why?
|
| Models, Biological | 2 | 2012 | 1437 | 0.120 |
Why?
|
| Hyperglycemia | 1 | 2017 | 220 | 0.120 |
Why?
|
| Preoperative Care | 3 | 2012 | 348 | 0.120 |
Why?
|
| Nicotine | 1 | 1996 | 139 | 0.120 |
Why?
|
| Angina Pectoris, Variant | 1 | 2014 | 1 | 0.120 |
Why?
|
| Random Allocation | 3 | 2005 | 417 | 0.120 |
Why?
|
| Caspase 3 | 2 | 2017 | 130 | 0.120 |
Why?
|
| Aortic Aneurysm, Thoracic | 2 | 1999 | 480 | 0.120 |
Why?
|
| Diet, Western | 1 | 2014 | 17 | 0.120 |
Why?
|
| Immune Complex Diseases | 1 | 1994 | 7 | 0.120 |
Why?
|
| Multivariate Analysis | 8 | 2007 | 1389 | 0.120 |
Why?
|
| Interleukin-6 | 1 | 2016 | 396 | 0.120 |
Why?
|
| Receptor, Adenosine A1 | 1 | 2014 | 1 | 0.120 |
Why?
|
| Adenosine A1 Receptor Antagonists | 1 | 2014 | 3 | 0.120 |
Why?
|
| Receptor, Adenosine A2A | 1 | 2014 | 10 | 0.120 |
Why?
|
| Adenosine A2 Receptor Antagonists | 1 | 2014 | 10 | 0.120 |
Why?
|
| Protein Binding | 1 | 2018 | 1733 | 0.120 |
Why?
|
| RNA | 1 | 2018 | 577 | 0.120 |
Why?
|
| Immunohistochemistry | 2 | 2011 | 1709 | 0.120 |
Why?
|
| Echocardiography, Doppler | 4 | 2005 | 171 | 0.120 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2014 | 147 | 0.120 |
Why?
|
| Ultrasonography | 4 | 2001 | 932 | 0.110 |
Why?
|
| Stem Cells | 1 | 2019 | 704 | 0.110 |
Why?
|
| Congresses as Topic | 2 | 2019 | 163 | 0.110 |
Why?
|
| Ezetimibe | 2 | 2019 | 95 | 0.110 |
Why?
|
| Hemarthrosis | 1 | 1993 | 3 | 0.110 |
Why?
|
| Organ Size | 2 | 2010 | 409 | 0.110 |
Why?
|
| Age Factors | 5 | 2024 | 2760 | 0.110 |
Why?
|
| Regression Analysis | 4 | 2005 | 746 | 0.110 |
Why?
|
| Calcium | 2 | 2010 | 1089 | 0.110 |
Why?
|
| Heart Valve Prosthesis Implantation | 2 | 2013 | 423 | 0.110 |
Why?
|
| Gene Knockdown Techniques | 1 | 2014 | 352 | 0.110 |
Why?
|
| Quinazolines | 1 | 2014 | 176 | 0.110 |
Why?
|
| Benzopyrans | 1 | 2013 | 19 | 0.110 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 2 | 2012 | 132 | 0.110 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2013 | 100 | 0.110 |
Why?
|
| Stellate Ganglion | 1 | 2013 | 9 | 0.110 |
Why?
|
| Tachycardia, Sinus | 1 | 2013 | 7 | 0.110 |
Why?
|
| Ethanolamines | 1 | 2013 | 29 | 0.110 |
Why?
|
| Atenolol | 1 | 2013 | 43 | 0.110 |
Why?
|
| Survival Analysis | 4 | 2018 | 1454 | 0.110 |
Why?
|
| Metabolic Syndrome | 1 | 2016 | 322 | 0.110 |
Why?
|
| S100 Calcium Binding Protein G | 1 | 1992 | 24 | 0.110 |
Why?
|
| Cardiology | 2 | 2016 | 463 | 0.100 |
Why?
|
| Mammary Arteries | 1 | 1992 | 26 | 0.100 |
Why?
|
| Diuretics | 1 | 2013 | 156 | 0.100 |
Why?
|
| Prevalence | 5 | 2011 | 2346 | 0.100 |
Why?
|
| Genetic Pleiotropy | 1 | 2012 | 24 | 0.100 |
Why?
|
| Microspheres | 2 | 2003 | 70 | 0.100 |
Why?
|
| Anesthetics, Local | 1 | 2013 | 78 | 0.100 |
Why?
|
| Chromosomes, Mammalian | 1 | 2012 | 42 | 0.100 |
Why?
|
| Arteriovenous Fistula | 1 | 1992 | 55 | 0.100 |
Why?
|
| Biomarkers | 6 | 2020 | 2919 | 0.100 |
Why?
|
| Valsartan | 1 | 2011 | 21 | 0.100 |
Why?
|
| Transcriptome | 1 | 2018 | 900 | 0.100 |
Why?
|
| Double-Blind Method | 4 | 2018 | 1542 | 0.100 |
Why?
|
| Dogs | 4 | 2003 | 772 | 0.100 |
Why?
|
| Brugada Syndrome | 1 | 2011 | 9 | 0.100 |
Why?
|
| Renin | 1 | 2011 | 89 | 0.100 |
Why?
|
| Nerve Block | 1 | 2013 | 67 | 0.100 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2013 | 281 | 0.100 |
Why?
|
| Kidney Failure, Chronic | 3 | 2020 | 852 | 0.100 |
Why?
|
| Chronic Disease | 3 | 2022 | 1144 | 0.100 |
Why?
|
| Troponin I | 1 | 2012 | 98 | 0.100 |
Why?
|
| Mice, Inbred Strains | 1 | 2011 | 318 | 0.100 |
Why?
|
| Radionuclide Imaging | 3 | 2005 | 152 | 0.090 |
Why?
|
| Oxidoreductases Acting on CH-NH Group Donors | 2 | 2002 | 26 | 0.090 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2013 | 408 | 0.090 |
Why?
|
| Emergency Medical Services | 2 | 2014 | 426 | 0.090 |
Why?
|
| Polygeline | 2 | 2001 | 2 | 0.090 |
Why?
|
| Plasma Substitutes | 2 | 2001 | 7 | 0.090 |
Why?
|
| Emergencies | 1 | 2012 | 172 | 0.090 |
Why?
|
| Diabetic Retinopathy | 1 | 2013 | 157 | 0.090 |
Why?
|
| CREB-Binding Protein | 1 | 2010 | 64 | 0.090 |
Why?
|
| Veterans | 1 | 2022 | 1680 | 0.090 |
Why?
|
| Sitagliptin Phosphate | 1 | 2010 | 6 | 0.090 |
Why?
|
| Cell Hypoxia | 1 | 2010 | 97 | 0.090 |
Why?
|
| Hypoxia | 1 | 2012 | 247 | 0.090 |
Why?
|
| Triglycerides | 1 | 2012 | 556 | 0.090 |
Why?
|
| Sex Factors | 4 | 2020 | 1222 | 0.090 |
Why?
|
| Antihypertensive Agents | 1 | 2013 | 390 | 0.090 |
Why?
|
| Retina | 1 | 2013 | 455 | 0.090 |
Why?
|
| Cholesterol | 1 | 2012 | 516 | 0.090 |
Why?
|
| Myocardial Contraction | 4 | 2009 | 258 | 0.080 |
Why?
|
| Receptors, Calcitonin Gene-Related Peptide | 1 | 2009 | 20 | 0.080 |
Why?
|
| Culture Media | 1 | 2010 | 183 | 0.080 |
Why?
|
| Lipids | 1 | 2012 | 508 | 0.080 |
Why?
|
| Insulin | 1 | 2014 | 1191 | 0.080 |
Why?
|
| Lipid Metabolism | 1 | 2012 | 352 | 0.080 |
Why?
|
| Sodium Chloride | 2 | 1999 | 97 | 0.080 |
Why?
|
| Decanoic Acids | 1 | 2008 | 2 | 0.080 |
Why?
|
| Hydroxy Acids | 1 | 2008 | 3 | 0.080 |
Why?
|
| Calcium Channel Blockers | 2 | 2022 | 113 | 0.080 |
Why?
|
| Models, Animal | 2 | 2012 | 467 | 0.080 |
Why?
|
| KATP Channels | 1 | 2008 | 6 | 0.080 |
Why?
|
| Cell Line | 2 | 2013 | 2769 | 0.080 |
Why?
|
| Nervous System Diseases | 1 | 2012 | 372 | 0.080 |
Why?
|
| Calcitonin Gene-Related Peptide | 1 | 2009 | 87 | 0.080 |
Why?
|
| ErbB Receptors | 1 | 2010 | 281 | 0.080 |
Why?
|
| Myocarditis | 1 | 1989 | 117 | 0.080 |
Why?
|
| Intubation, Gastrointestinal | 1 | 2008 | 52 | 0.080 |
Why?
|
| Tyrphostins | 1 | 2008 | 14 | 0.080 |
Why?
|
| Ligation | 1 | 2008 | 133 | 0.080 |
Why?
|
| Drug Combinations | 2 | 2007 | 263 | 0.080 |
Why?
|
| Electrophoretic Mobility Shift Assay | 1 | 2008 | 48 | 0.080 |
Why?
|
| Multicenter Studies as Topic | 2 | 2007 | 259 | 0.080 |
Why?
|
| Mitochondria, Heart | 1 | 2008 | 62 | 0.080 |
Why?
|
| Fluorocarbons | 2 | 1999 | 57 | 0.080 |
Why?
|
| Electrocardiography, Ambulatory | 2 | 2006 | 60 | 0.080 |
Why?
|
| Janus Kinases | 1 | 2008 | 31 | 0.080 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2010 | 343 | 0.080 |
Why?
|
| Propranolol | 1 | 2008 | 128 | 0.080 |
Why?
|
| Sildenafil Citrate | 2 | 2006 | 50 | 0.080 |
Why?
|
| Sulfones | 2 | 2006 | 66 | 0.080 |
Why?
|
| Magnetic Resonance Angiography | 2 | 2006 | 164 | 0.080 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2011 | 1292 | 0.080 |
Why?
|
| Angioplasty, Balloon | 2 | 2011 | 143 | 0.070 |
Why?
|
| Data Interpretation, Statistical | 1 | 2008 | 199 | 0.070 |
Why?
|
| Purines | 2 | 2006 | 107 | 0.070 |
Why?
|
| Serine | 1 | 2008 | 174 | 0.070 |
Why?
|
| Theophylline | 1 | 2007 | 29 | 0.070 |
Why?
|
| Creatine Kinase, BB Form | 1 | 2007 | 5 | 0.070 |
Why?
|
| Survival | 1 | 2007 | 19 | 0.070 |
Why?
|
| Butadienes | 1 | 2007 | 19 | 0.070 |
Why?
|
| 5'-Nucleotidase | 1 | 2007 | 16 | 0.070 |
Why?
|
| Brachial Artery | 1 | 2007 | 34 | 0.070 |
Why?
|
| Creatine Kinase | 2 | 1998 | 54 | 0.070 |
Why?
|
| Organ Culture Techniques | 1 | 2007 | 155 | 0.070 |
Why?
|
| CD36 Antigens | 1 | 2007 | 34 | 0.070 |
Why?
|
| Immunologic Factors | 1 | 2008 | 172 | 0.070 |
Why?
|
| Models, Chemical | 1 | 2007 | 86 | 0.070 |
Why?
|
| Nitroso Compounds | 1 | 2006 | 8 | 0.070 |
Why?
|
| Colitis, Ulcerative | 1 | 1989 | 210 | 0.070 |
Why?
|
| Biotin | 1 | 2006 | 40 | 0.070 |
Why?
|
| Nitriles | 1 | 2007 | 143 | 0.070 |
Why?
|
| Inositol Polyphosphate 5-Phosphatases | 1 | 2006 | 6 | 0.070 |
Why?
|
| Constriction, Pathologic | 3 | 1997 | 226 | 0.070 |
Why?
|
| Oncogene Protein v-akt | 1 | 2006 | 30 | 0.070 |
Why?
|
| Amidines | 1 | 2006 | 1 | 0.070 |
Why?
|
| Benzylamines | 1 | 2006 | 17 | 0.070 |
Why?
|
| Gene Expression | 1 | 2011 | 1579 | 0.070 |
Why?
|
| Hypercalcemia | 1 | 2006 | 40 | 0.070 |
Why?
|
| Feasibility Studies | 2 | 1999 | 721 | 0.070 |
Why?
|
| Obesity | 1 | 2016 | 2080 | 0.060 |
Why?
|
| Phosphoric Monoester Hydrolases | 1 | 2006 | 101 | 0.060 |
Why?
|
| Alanine | 1 | 2006 | 182 | 0.060 |
Why?
|
| Blood Vessel Prosthesis Implantation | 2 | 2004 | 524 | 0.060 |
Why?
|
| Forecasting | 2 | 2005 | 349 | 0.060 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2013 | 681 | 0.060 |
Why?
|
| Prostaglandin-E Synthases | 1 | 2005 | 12 | 0.060 |
Why?
|
| Exercise | 2 | 2005 | 784 | 0.060 |
Why?
|
| Isoxazoles | 1 | 2005 | 31 | 0.060 |
Why?
|
| Polymerase Chain Reaction | 1 | 2008 | 1583 | 0.060 |
Why?
|
| Regional Blood Flow | 3 | 2007 | 205 | 0.060 |
Why?
|
| Pilot Projects | 3 | 2013 | 1352 | 0.060 |
Why?
|
| Reference Values | 2 | 2003 | 693 | 0.060 |
Why?
|
| Polyethylene Terephthalates | 1 | 2004 | 40 | 0.060 |
Why?
|
| Mitral Valve | 2 | 2004 | 245 | 0.060 |
Why?
|
| Metabolic Clearance Rate | 1 | 2004 | 143 | 0.060 |
Why?
|
| Statistics, Nonparametric | 2 | 2018 | 412 | 0.060 |
Why?
|
| Enzyme Inhibitors | 1 | 2007 | 581 | 0.060 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2006 | 304 | 0.060 |
Why?
|
| Brachiocephalic Trunk | 1 | 2004 | 34 | 0.060 |
Why?
|
| Nitric Oxide | 1 | 2007 | 446 | 0.060 |
Why?
|
| Postoperative Period | 2 | 2012 | 330 | 0.060 |
Why?
|
| Graft Occlusion, Vascular | 1 | 2004 | 87 | 0.060 |
Why?
|
| Swine Diseases | 1 | 2004 | 35 | 0.060 |
Why?
|
| Blood Flow Velocity | 3 | 2005 | 446 | 0.060 |
Why?
|
| Immunoglobulin Fab Fragments | 1 | 2004 | 66 | 0.060 |
Why?
|
| Pyridones | 1 | 2024 | 111 | 0.060 |
Why?
|
| Pneumonia | 2 | 2020 | 326 | 0.060 |
Why?
|
| Catheter Ablation | 2 | 2004 | 226 | 0.060 |
Why?
|
| Age of Onset | 2 | 2002 | 563 | 0.050 |
Why?
|
| Prosthesis Failure | 2 | 2004 | 145 | 0.050 |
Why?
|
| Dilatation, Pathologic | 1 | 2003 | 89 | 0.050 |
Why?
|
| Immersion | 1 | 2002 | 8 | 0.050 |
Why?
|
| Clot Retraction | 1 | 2002 | 6 | 0.050 |
Why?
|
| Pregnancy | 1 | 2015 | 6858 | 0.050 |
Why?
|
| Physical Examination | 1 | 2004 | 162 | 0.050 |
Why?
|
| NG-Nitroarginine Methyl Ester | 1 | 2003 | 59 | 0.050 |
Why?
|
| Transfection | 2 | 2017 | 1075 | 0.050 |
Why?
|
| Cardiac Tamponade | 2 | 2005 | 36 | 0.050 |
Why?
|
| 3' Untranslated Regions | 2 | 2013 | 166 | 0.050 |
Why?
|
| Heart Septum | 1 | 2002 | 57 | 0.050 |
Why?
|
| Minimally Invasive Surgical Procedures | 1 | 2004 | 188 | 0.050 |
Why?
|
| Network Meta-Analysis | 1 | 2022 | 40 | 0.050 |
Why?
|
| Case-Control Studies | 3 | 2002 | 3209 | 0.050 |
Why?
|
| Body Composition | 1 | 2004 | 473 | 0.050 |
Why?
|
| Health Personnel | 1 | 2006 | 494 | 0.050 |
Why?
|
| Streptozocin | 1 | 2021 | 25 | 0.050 |
Why?
|
| Esophagus | 1 | 2003 | 207 | 0.050 |
Why?
|
| Homocysteine | 1 | 2002 | 121 | 0.050 |
Why?
|
| Corticosterone | 1 | 2021 | 61 | 0.050 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2018 | 974 | 0.050 |
Why?
|
| Ketones | 1 | 2021 | 25 | 0.050 |
Why?
|
| Gene Expression Profiling | 2 | 2018 | 1672 | 0.050 |
Why?
|
| Milrinone | 1 | 2001 | 29 | 0.050 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2005 | 536 | 0.050 |
Why?
|
| Hospital Costs | 1 | 2022 | 176 | 0.050 |
Why?
|
| Venous Thrombosis | 1 | 2003 | 180 | 0.050 |
Why?
|
| Colloids | 1 | 2000 | 16 | 0.050 |
Why?
|
| Vascular Surgical Procedures | 1 | 2006 | 523 | 0.050 |
Why?
|
| Mechanistic Target of Rapamycin Complex 2 | 1 | 2020 | 28 | 0.050 |
Why?
|
| Blood Vessel Prosthesis | 1 | 2003 | 325 | 0.040 |
Why?
|
| Epinephrine | 1 | 2021 | 175 | 0.040 |
Why?
|
| Mortality | 1 | 2022 | 221 | 0.040 |
Why?
|
| Postoperative Care | 1 | 2002 | 293 | 0.040 |
Why?
|
| Water | 1 | 2021 | 177 | 0.040 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2006 | 707 | 0.040 |
Why?
|
| Mass Screening | 2 | 2022 | 770 | 0.040 |
Why?
|
| Drug Monitoring | 1 | 2021 | 155 | 0.040 |
Why?
|
| Embolism, Air | 1 | 2000 | 24 | 0.040 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2020 | 91 | 0.040 |
Why?
|
| Radiotherapy | 1 | 2020 | 138 | 0.040 |
Why?
|
| Suction | 1 | 2000 | 56 | 0.040 |
Why?
|
| Ventricular Dysfunction | 1 | 2000 | 24 | 0.040 |
Why?
|
| Solubility | 1 | 1999 | 135 | 0.040 |
Why?
|
| Endocarditis | 1 | 2020 | 100 | 0.040 |
Why?
|
| Systole | 1 | 2000 | 197 | 0.040 |
Why?
|
| Evaluation Studies as Topic | 2 | 1998 | 256 | 0.040 |
Why?
|
| Kinetics | 1 | 2001 | 1316 | 0.040 |
Why?
|
| Premedication | 1 | 1999 | 44 | 0.040 |
Why?
|
| C-Reactive Protein | 1 | 2002 | 404 | 0.040 |
Why?
|
| Hemostasis | 1 | 2019 | 66 | 0.040 |
Why?
|
| Heart Septal Defects, Ventricular | 1 | 2000 | 133 | 0.040 |
Why?
|
| Ulcer | 1 | 1999 | 41 | 0.040 |
Why?
|
| Databases, Factual | 2 | 2020 | 1137 | 0.040 |
Why?
|
| Europe | 1 | 2019 | 358 | 0.040 |
Why?
|
| Heart Valve Diseases | 1 | 2000 | 167 | 0.040 |
Why?
|
| Patient Readmission | 1 | 2022 | 367 | 0.040 |
Why?
|
| Infusions, Intravenous | 2 | 1998 | 543 | 0.040 |
Why?
|
| Enkephalin, D-Penicillamine (2,5)- | 2 | 2009 | 3 | 0.040 |
Why?
|
| Denmark | 1 | 2018 | 31 | 0.040 |
Why?
|
| Disease Management | 1 | 2002 | 512 | 0.040 |
Why?
|
| Serum Albumin, Human | 1 | 1998 | 7 | 0.040 |
Why?
|
| Soft Tissue Injuries | 1 | 1998 | 11 | 0.040 |
Why?
|
| Hematoma | 1 | 1999 | 85 | 0.040 |
Why?
|
| Atherectomy, Coronary | 1 | 1997 | 9 | 0.040 |
Why?
|
| Diagnostic Tests, Routine | 1 | 1999 | 116 | 0.040 |
Why?
|
| Cerebrovascular Disorders | 1 | 2018 | 114 | 0.040 |
Why?
|
| Antibodies, Monoclonal | 1 | 2004 | 1005 | 0.040 |
Why?
|
| Confidence Intervals | 1 | 1998 | 272 | 0.040 |
Why?
|
| Saphenous Vein | 1 | 1997 | 43 | 0.040 |
Why?
|
| Cluster Analysis | 1 | 2018 | 385 | 0.040 |
Why?
|
| Sudan | 1 | 1997 | 4 | 0.040 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 1998 | 129 | 0.040 |
Why?
|
| Los Angeles | 1 | 1997 | 18 | 0.040 |
Why?
|
| Dietary Supplements | 1 | 2021 | 460 | 0.040 |
Why?
|
| Cats | 1 | 1997 | 114 | 0.040 |
Why?
|
| Coroners and Medical Examiners | 1 | 1997 | 16 | 0.040 |
Why?
|
| Tetrazolium Salts | 1 | 1997 | 15 | 0.040 |
Why?
|
| Aging | 1 | 2024 | 1156 | 0.040 |
Why?
|
| Mice, Obese | 1 | 2017 | 77 | 0.040 |
Why?
|
| Cytoprotection | 1 | 2017 | 37 | 0.040 |
Why?
|
| Emergency Treatment | 1 | 1998 | 86 | 0.040 |
Why?
|
| Cytochromes c | 1 | 2017 | 51 | 0.040 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2006 | 1086 | 0.040 |
Why?
|
| Coenzymes | 1 | 1996 | 12 | 0.040 |
Why?
|
| Apolipoproteins E | 1 | 2017 | 188 | 0.040 |
Why?
|
| Data Collection | 1 | 1999 | 378 | 0.040 |
Why?
|
| Transcription Factors | 1 | 2007 | 2586 | 0.040 |
Why?
|
| Doxorubicin | 1 | 1998 | 306 | 0.030 |
Why?
|
| Oxidative Stress | 2 | 2017 | 788 | 0.030 |
Why?
|
| Electric Stimulation | 1 | 1997 | 318 | 0.030 |
Why?
|
| Hypercholesterolemia | 1 | 2019 | 226 | 0.030 |
Why?
|
| Liver Diseases | 1 | 2020 | 385 | 0.030 |
Why?
|
| Cell Adhesion | 1 | 1997 | 328 | 0.030 |
Why?
|
| Species Specificity | 1 | 1997 | 543 | 0.030 |
Why?
|
| Cardiomyopathy, Dilated | 1 | 1998 | 214 | 0.030 |
Why?
|
| Sarcoma, Kaposi | 1 | 1998 | 119 | 0.030 |
Why?
|
| Cineradiography | 1 | 1996 | 3 | 0.030 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 1998 | 234 | 0.030 |
Why?
|
| Cardiac Output, Low | 1 | 1996 | 66 | 0.030 |
Why?
|
| Sequence Analysis, RNA | 1 | 2018 | 367 | 0.030 |
Why?
|
| Running | 1 | 1996 | 36 | 0.030 |
Why?
|
| Coronary Care Units | 1 | 1996 | 36 | 0.030 |
Why?
|
| Electrodes | 1 | 1996 | 97 | 0.030 |
Why?
|
| History, 21st Century | 1 | 2016 | 256 | 0.030 |
Why?
|
| Single-Blind Method | 1 | 1996 | 231 | 0.030 |
Why?
|
| Long QT Syndrome | 1 | 1996 | 86 | 0.030 |
Why?
|
| Rural Population | 1 | 1997 | 236 | 0.030 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2019 | 489 | 0.030 |
Why?
|
| Neutrophils | 1 | 1997 | 382 | 0.030 |
Why?
|
| History, 20th Century | 1 | 2016 | 370 | 0.030 |
Why?
|
| Skin | 1 | 1998 | 498 | 0.030 |
Why?
|
| Treatment Failure | 2 | 2007 | 332 | 0.030 |
Why?
|
| Cytokines | 1 | 2020 | 1258 | 0.030 |
Why?
|
| Genotype | 2 | 2017 | 2534 | 0.030 |
Why?
|
| Purkinje Fibers | 1 | 1993 | 6 | 0.030 |
Why?
|
| Renal Dialysis | 1 | 2020 | 830 | 0.030 |
Why?
|
| Reperfusion | 1 | 1993 | 23 | 0.030 |
Why?
|
| Estradiol | 1 | 1996 | 534 | 0.030 |
Why?
|
| Mitral Valve Prolapse | 1 | 1993 | 28 | 0.030 |
Why?
|
| Hyperhomocysteinemia | 2 | 2004 | 38 | 0.030 |
Why?
|
| Serum Sickness | 1 | 1993 | 2 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2022 | 3266 | 0.030 |
Why?
|
| Death, Sudden | 1 | 1993 | 46 | 0.030 |
Why?
|
| Rats, Inbred Dahl | 1 | 2013 | 3 | 0.030 |
Why?
|
| Nebivolol | 1 | 2013 | 4 | 0.030 |
Why?
|
| Phosphatidylinositol 3-Kinase | 1 | 2013 | 26 | 0.030 |
Why?
|
| Blood Coagulation Tests | 1 | 1993 | 60 | 0.030 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2018 | 862 | 0.030 |
Why?
|
| cdc42 GTP-Binding Protein | 1 | 2013 | 31 | 0.030 |
Why?
|
| Binding, Competitive | 1 | 2013 | 182 | 0.030 |
Why?
|
| Hypotension | 1 | 1994 | 175 | 0.030 |
Why?
|
| Antioxidants | 1 | 1995 | 332 | 0.030 |
Why?
|
| Cineangiography | 2 | 2004 | 15 | 0.030 |
Why?
|
| Thoracic Injuries | 1 | 1993 | 87 | 0.030 |
Why?
|
| Immunoglobulins | 1 | 2013 | 169 | 0.030 |
Why?
|
| Activating Transcription Factor 2 | 1 | 2012 | 15 | 0.030 |
Why?
|
| Linear Models | 1 | 1994 | 654 | 0.030 |
Why?
|
| Genes, Reporter | 1 | 2013 | 383 | 0.020 |
Why?
|
| Exercise Test | 2 | 2005 | 247 | 0.020 |
Why?
|
| Fatty Acids, Nonesterified | 1 | 2012 | 136 | 0.020 |
Why?
|
| Leptin | 1 | 2013 | 209 | 0.020 |
Why?
|
| Adiponectin | 1 | 2012 | 109 | 0.020 |
Why?
|
| Heart Arrest | 1 | 1996 | 342 | 0.020 |
Why?
|
| Wounds, Nonpenetrating | 1 | 1993 | 199 | 0.020 |
Why?
|
| Jaundice | 1 | 1991 | 27 | 0.020 |
Why?
|
| Placebos | 1 | 2011 | 238 | 0.020 |
Why?
|
| Angiography | 2 | 2004 | 202 | 0.020 |
Why?
|
| Methylenetetrahydrofolate Reductase (NADPH2) | 2 | 2002 | 70 | 0.020 |
Why?
|
| Glomerular Filtration Rate | 1 | 2013 | 470 | 0.020 |
Why?
|
| Binding Sites | 1 | 2013 | 1291 | 0.020 |
Why?
|
| Surgical Wound Infection | 1 | 2012 | 260 | 0.020 |
Why?
|
| Recombinant Proteins | 1 | 1993 | 1363 | 0.020 |
Why?
|
| Adrenergic beta-2 Receptor Antagonists | 1 | 2009 | 13 | 0.020 |
Why?
|
| Indomethacin | 1 | 1989 | 84 | 0.020 |
Why?
|
| Homozygote | 2 | 2002 | 535 | 0.020 |
Why?
|
| Adrenergic beta-2 Receptor Agonists | 1 | 2009 | 62 | 0.020 |
Why?
|
| Drug Administration Routes | 1 | 2008 | 30 | 0.020 |
Why?
|
| Cell Death | 1 | 2009 | 241 | 0.020 |
Why?
|
| Sepsis | 1 | 2012 | 471 | 0.020 |
Why?
|
| Primary Health Care | 1 | 2014 | 747 | 0.020 |
Why?
|
| Hyperemia | 1 | 2007 | 25 | 0.020 |
Why?
|
| Phenotype | 1 | 2017 | 4196 | 0.020 |
Why?
|
| Vascular Resistance | 1 | 2007 | 189 | 0.020 |
Why?
|
| Vasodilation | 1 | 2007 | 191 | 0.020 |
Why?
|
| Ultrasonography, Doppler | 1 | 2007 | 197 | 0.020 |
Why?
|
| Organotechnetium Compounds | 1 | 2005 | 12 | 0.020 |
Why?
|
| Organophosphorus Compounds | 1 | 2005 | 23 | 0.020 |
Why?
|
| Internationality | 1 | 2006 | 126 | 0.020 |
Why?
|
| AC133 Antigen | 1 | 2005 | 35 | 0.020 |
Why?
|
| False Positive Reactions | 1 | 2005 | 140 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2005 | 65 | 0.020 |
Why?
|
| Isometric Contraction | 1 | 2005 | 19 | 0.020 |
Why?
|
| Calcium Signaling | 1 | 2007 | 237 | 0.020 |
Why?
|
| Cell Count | 1 | 2005 | 249 | 0.020 |
Why?
|
| Plasminogen Activators | 1 | 2004 | 20 | 0.020 |
Why?
|
| Safety | 1 | 2005 | 213 | 0.020 |
Why?
|
| Body Surface Area | 1 | 2004 | 31 | 0.010 |
Why?
|
| Telecommunications | 1 | 2004 | 19 | 0.010 |
Why?
|
| Aortography | 1 | 2004 | 146 | 0.010 |
Why?
|
| Adolescent | 1 | 2002 | 18730 | 0.010 |
Why?
|
| Unnecessary Procedures | 1 | 2004 | 54 | 0.010 |
Why?
|
| Anastomosis, Surgical | 1 | 2004 | 167 | 0.010 |
Why?
|
| Ventricular Fibrillation | 1 | 2004 | 51 | 0.010 |
Why?
|
| Edema | 1 | 2004 | 134 | 0.010 |
Why?
|
| Antigens, CD | 1 | 2005 | 424 | 0.010 |
Why?
|
| Ethanol | 1 | 2004 | 160 | 0.010 |
Why?
|
| Glycoproteins | 1 | 2005 | 363 | 0.010 |
Why?
|
| Radionuclide Ventriculography | 1 | 2001 | 5 | 0.010 |
Why?
|
| Cyclic Nucleotide Phosphodiesterases, Type 3 | 1 | 2001 | 3 | 0.010 |
Why?
|
| Thallium Radioisotopes | 1 | 2001 | 14 | 0.010 |
Why?
|
| 3',5'-Cyclic-AMP Phosphodiesterases | 1 | 2001 | 22 | 0.010 |
Why?
|
| Transducers | 1 | 2001 | 25 | 0.010 |
Why?
|
| Ventricular Pressure | 1 | 2000 | 43 | 0.010 |
Why?
|
| Retreatment | 1 | 2000 | 74 | 0.010 |
Why?
|
| Software | 1 | 2004 | 669 | 0.010 |
Why?
|
| Echocardiography, Doppler, Pulsed | 1 | 1999 | 19 | 0.010 |
Why?
|
| Gene Frequency | 1 | 1999 | 706 | 0.010 |
Why?
|
| Microscopy, Electron | 1 | 1998 | 396 | 0.010 |
Why?
|
| Hot Temperature | 1 | 1998 | 135 | 0.010 |
Why?
|
| Patient Selection | 1 | 2001 | 645 | 0.010 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2000 | 274 | 0.010 |
Why?
|
| Folic Acid | 1 | 1999 | 290 | 0.010 |
Why?
|
| Fatal Outcome | 1 | 1998 | 348 | 0.010 |
Why?
|
| Aortic Diseases | 1 | 1999 | 177 | 0.010 |
Why?
|
| Tilt-Table Test | 1 | 1996 | 9 | 0.010 |
Why?
|
| Exercise Tolerance | 1 | 1996 | 72 | 0.010 |
Why?
|
| Diltiazem | 1 | 1994 | 13 | 0.010 |
Why?
|
| Alleles | 1 | 1999 | 1587 | 0.010 |
Why?
|
| Verapamil | 1 | 1994 | 52 | 0.010 |
Why?
|
| Young Adult | 1 | 2008 | 8627 | 0.010 |
Why?
|
| Electrophysiology | 1 | 1993 | 270 | 0.010 |
Why?
|
| Glucosephosphate Dehydrogenase Deficiency | 1 | 1991 | 9 | 0.010 |
Why?
|
| Liver Function Tests | 1 | 1991 | 103 | 0.010 |
Why?
|
| Bilirubin | 1 | 1991 | 128 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 1999 | 3064 | 0.010 |
Why?
|
| Mutation | 1 | 2002 | 5738 | 0.000 |
Why?
|